Either they have nothing to report (which is doubtful; they have something they intend to report; but the compilation isn't complete yet; or, they have something to report, but they're waiting for a more strategic time to release it. This is always the case with micro-cap biotech companies.

Waiting does become tedious and the share price suffers. History tell us that news will disappoint or it's "meh" at best. Unfortunately, the ESMO presentations and previous letters to shareholders have us anticipating important news on a weekly basis (Tuesdays). So we wait.

None of this provides an adequate excuse for not responding to shareholder questions or communicating as promised. Some of us were old when the Charlie Sheen HIV news came out. We are older now.